Can Targeting the TCA Cycle Be a Therapeutic Strategy?
Given the dependence of cancer cells on the TCA cycle for growth and survival, targeting TCA cycle enzymes represents a promising therapeutic strategy. Inhibitors of mutant IDH1 and IDH2 are already in clinical use, showing efficacy in treating certain cancers. Additionally, targeting glutaminase, which converts glutamine to glutamate, has shown potential in preclinical studies. However, the complexity of cancer metabolism necessitates a careful approach to avoid toxicity in normal cells.
